Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Buprenorphine for Suicidal Ideation in Major Depression
NCT05427981Phase 3Withdrawn
- Sponsor
- New York State Psychiatric Institute
- Start
- Oct 2022
- Primary completion
- Jan 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of buprenorphine in suicidal ideation, major depressive disorder (MDD), sponsored by New York State Psychiatric Institute. Planned start Oct 2022; status: withdrawn.
02
Drugs
buprenorphine
03
Conditions
suicidal ideationmajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05427981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05427981.